Changes in drug coverage generosity and untreated serious mental illness transitioning from Medicaid to Medicare part D

JAMA Psychiatry

Volumn 72, Issue 2, 2015, Pages 179-188

  Madden, Jeanne M ^a   Adams, Alyce S ^b   LeCates, Robert F ^a   Ross Degnan, Dennis ^a   Zhang, Fang ^a   Huskamp, Haiden A ^a   Gilden, Daniel M ^c   Soumerai, Stephen B ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DIVISION OF RESEARCH   (United States)

^c JEN Associates Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; LITHIUM; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT;

ADULT; ARTICLE; BIPOLAR DISORDER; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG USE; FEMALE; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; MEDICAID; MEDICARE; MEDICATION COMPLIANCE; MIDDLE AGED; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PRESCRIPTION; PREVALENCE; SCHIZOPHRENIA; TIME SERIES ANALYSIS; ECONOMICS; STATISTICS AND NUMERICAL DATA; UNITED STATES; YOUNG ADULT;

ADULT; BIPOLAR DISORDER; DRUG PRESCRIPTIONS; FEMALE; HUMANS; MALE; MEDICAID; MEDICARE PART D; MIDDLE AGED; PREVALENCE; PSYCHOTROPIC DRUGS; SCHIZOPHRENIA; UNITED STATES; YOUNG ADULT;

EID: 84922221793     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2014.1259     Document Type: Article

References (47)

1. Briesacher BA, Zhao Y, Madden JM, et al. Medicare Part D and changes in prescription drug use and cost burden: national estimates for the Medicare population, 2000 to 2007. Med Care. 2011;49(9):834-841.
2. Polinski JM, Kilabuk E, Schneeweiss S, Brennan T, Shrank WH. Changes in drug use and out-of-pocket costs associated with Medicare Part D implementation: a systematic review. J Am Geriatr Soc. 2010;58(9):1764-1779.
3. Neuman P, Cubanski J. Medicare Part D update-lessons learned and unfinished business. N Engl J Med. 2009;361(4):406-414.
4. Donohue JM, Huskamp HA, Zuvekas SH. Dual eligibles with mental disorders and Medicare Part D: how are they faring? Health Aff (Millwood). 2009;28(3):746-759.
5. Shrank WH, Patrick AR, Pedan A, et al. The effect of transitioning to Medicare Part D drug coverage in seniors dually eligible for Medicare and Medicaid. J AmGeriatr Soc. 2008;56(12):2304-2310.
6. Basu A, YinW, Alexander GC. Impact of Medicare Part D on Medicare-Medicaid dual-eligible beneficiaries' prescription utilization and expenditures. Health Serv Res. 2010;45(1):133-151.
7. Chen H, Nwangwu A, Aparasu R, Essien E, Sun S, Lee K. The impact of Medicare Part D on psychotropic utilization and financial burden for community-based seniors. Psychiatr Serv. 2008;59 (10):1191-1197.
8. McGrath J, Saha S, Chant D,Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev. 2008;30: 67-76.
9. Merikangas KR, Akiskal HS, Angst J, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry. 2007;64 (5):543-552.
10. Annual statistical report on the Social Security disability insurance program, 2011. Social Security Administration (SSA),Office of Retirement and Disability Policy, 2012. SSA Publication 13-11826. http: //www. ssa. gov/policy/docs/statcomps/di-asr/2011/di -asr11. pdf. Released July 2012. Accessed April 7, 2014.
11. Velligan DI,Weiden PJ, Sajatovic M, et al; Expert Consensus Panel on Adherence Problems in Serious and Persistent Mental Illness. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry. 2009;70(suppl 4):1-46.
12. Sajatovic M, Davies M, Hrouda DR. Enhancement of treatment adherence among patients with bipolar disorder. Psychiatr Serv. 2004;55(3):264-269.
13. Hawton K, Sutton L, Haw C, Sinclair J, Deeks JJ. Schizophrenia and suicide: systematic review of risk factors. Br J Psychiatry. 2005;187:9-20.
14. Gilmer TP, Dolder CR, Lacro JP, et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiarieswith schizophrenia. AmJ Psychiatry. 2004;161(4):692-699.
15. The Management of Bipolar DisorderWorking Group. VA/DoD Clinical Practice Guideline for Management of Bipolar Disorder in Adults. Washington, DC: US Departments of Veterans Affairs and Defense; 2010.
16. Soumerai SB, Zhang F, Ross-Degnan D, et al. Use of atypical antipsychotic drugs for schizophrenia in Maine Medicaid following a policy change. Health Aff (Millwood). 2008;27(3):w185-w195.
17. Lu CY, Adams AS, Ross-Degnan D, et al. Association between prior authorization for medications and health service use by Medicaid patients with bipolar disorder. Psychiatr Serv. 2011; 62(2):186-193.
18. Smith VK, Gifford K, Ellis E, Rudowitz R, Synder L. Medicaid today; preparing for tomorrow a look at state Medicaid program spending, enrollment and policy trends: results from a 50-state Medicaid budget survey for state fiscal years 2012 and 2013. Kaiser Family Foundation website. http://kff. org /medicaid/report/medicaid-today-preparing-for-tomorrow-a-look-at-state-medicaid-program-spending-enrollment-and-policy-trends-results-from-a-50-state-medicaid-budget-survey-for-state-fiscal-years-2012-and-2013/. Published October 2012. Accessed October 30, 2014.
19. Medicaid benefits: prescription drugs. Kaiser Foundation website. http://kff. org/medicaid/state-indicator/prescription-drugs/. Accessed March 25, 2014.
20. Soumerai SB, Avorn J, Ross-Degnan D, Gortmaker S. Payment restrictions for prescription drugs under Medicaid: effects on therapy, cost, and equity. N Engl J Med. 1987;317(9):550-556.
21. Martin BC, McMillan JA. The impact of implementing a more restrictive prescription limit on Medicaid recipients: effects on cost, therapy, and out-of-pocket expenditures. Med Care. 1996; 34(7):686-701.
22. Elliott RA, Majumdar SR, GillickMR, Soumerai SB. Benefits and consequences for the poor and the disabled. N Engl J Med. 2005;353(26):2739-2741.
23. Morden NE, Garrison LP Jr. Implications of Part D for mentally ill dual eligibles: a challenge for Medicare. Health Aff (Millwood). 2006;25(2):491-500.
24. Shadish WR, Cook TD, Campbell DT. Experimental and Quasi-Experimental Designs for Generalized Causal Inference. Boston, MA: Cengage Learning; 2001.
25. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther. 2002;27(4):299-309.
26. Ross-Degnan D, Simoni-Wastila L, Brown JS, et al. A controlled study of the effects of state surveillance on indicators of problematic and non-problematic benzodiazepine use in a Medicaid population. Int J PsychiatryMed. 2004;34(2):103-123.
27. Marcus SC, Olfson M. Outpatient antipsychotic treatment and inpatient costs of schizophrenia. Schizophr Bull. 2008;34(1):173-180.
28. Crowley JS, Ashner D, Elam L. State outpatient prescription drug policies: findings from a national survey, 2005 update. Kaiser Family Foundation website. http://kaiserfamilyfoundation. files. wordpress com/2013/01/state-medicaid-outpatient-prescription-drug-policies-findings-from-a-national-survey-2005-update-report. pdf. Published October 2005. Accessed October 30, 2014.
29. Hearne J. Report for Congress: Prescription Drug Coverage Under Medicaid: February 21, 2006-RL30726. Washington, DC: Congressional Research Service; 2013.
30. Pharmaceutical benefits under state medical assistance programs, 2004. National Pharmaceutical Councilwebsite. http://www. npcnow. org/publication /pharmaceutical-benefits-under-state-medical-assistance-programs-2004. Accessed November 6, 2014.
31. Pharmaceutical benefits under state medical assistance programs, 2005. National Pharmaceutical Councilwebsite. http://www. npcnow. org/publication /pharmaceutical-benefits-under-state-medical-assistance-programs-2005. Accessed November 6, 2014.
32. Pharmaceutical benefits under state medical assistance programs, 2007. National Pharmaceutical Councilwebsite. http://www. npcnow. org/publication /pharmaceutical-benefits-under-state-medical-assistance-programs-2007. Accessed October 30, 2014.
33. Soumerai SB, Ross-Degnan D, Avorn J, McLaughlin TJ, Choodnovskiy I. Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes. N Engl J Med. 1991;325(15):1072-1077.
34. Pope GC, Kautter J, Ellis RP, et al. Risk adjustment of Medicare capitation payments using the CMS-HCC model. Health Care Financ Rev. 2004;25(4):119-141.
35. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry. 2002;159(4 suppl):1-50.
36. Smith V, Gifford K, Kramer S, Elam L. The transition of dual eligibles to Medicare Part D prescription drug coverage: state actions during implementation. Kaiser Family Foundation website. http://kff. org/medicaid/report/the-transition-of-dual-eligibles-to-medicare/. Published February 2006. Accessed October 30, 2014.
37. Soumerai SB, McLaughlin TJ, Ross-Degnan D, Casteris CS, Bollini P. Effects of a limit on Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. N Engl J Med. 1994;331(10):650-655.
38. Bambauer KZ, Sabin JE, Soumerai SB. The exclusion of benzodiazepine coverage in Medicare: simple steps for avoiding a public health crisis. Psychiatr Serv. 2005;56(9):1143-1146.
39. Oberlander J. Beyond repeal-the future of health care reform. N Engl J Med. 2010;363(24): 2277-2279.
40. Rosenbaum S. Realigning the social order: the Patient Protection and Affordable Care Act and the US health insurance system. J Health Biomed Law. 2011;7:1-31.
41. Kenney GM, Huntress M, Buettgens M, Lynch V, Resnick D. State and local coverage changes under full implementation of the Affordable Care Act. Kaiser Family Foundationwebsite. http://kff. org/health-reform /report/state-and-local-coverage-changes-under-full-implementation-of-the-affordable-care-act/. Published July 31, 2013. AccessedOctober 30, 2014.
42. Wharam JF, Ross-Degnan D, Rosenthal MB. The ACA and high-deductible insurance-strategies for sharpening a blunt instrument. N Engl J Med. 2013; 369(16):1481-1484.
43. Adams AS, Madden JM, Zhang F, et al. Changes in use of lipid-lowering medications among black and white dual enrollees with diabetes transitioning from Medicaid to Medicare Part D drug coverage. Med Care. 2014;52(8):695-703.
44. Huskamp HA, Stevenson DG, Donohue JM, Newhouse JP, Keating NL. Coverage and prior authorization of psychotropic drugs under Medicare Part D. Psychiatr Serv. 2007;58(3):308-310.
45. Cutrona SL,Woolhandler S, Lasser KE, Bor DH, McCormick D, Himmelstein DU. Characteristics of recipients of free prescription drug samples: a nationally representative analysis. Am J Public Health. 2008;98(2):284-289.
46. Hoadley J, Summer L, Hargrave E, Cubanski J. Medicare Part D prescription drug plans: the marketplace in 2013 and key trends, 2006-2013. Kaiser Family Foundation website. http://kff. org/medicare /issue-brief/medicare-part-d-prescription-drug-plans-the-marketplace-in-2013-and-key-trends-2006-2013/. Published December 11, 2013. Accessed October 30, 2014.
47. Hoadley J, Cubanski J, Hargrave E, Summer L. Medicare Part D: a first look at plan offerings in 2014. Kaiser Family Foundation website. http://kff org/medicare/issue-brief/medicare-part-d-a-first-look-at-plan-offerings-in-2014/. Published October 10, 2013. Accessed October 30, 2014.